Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 6/20 | 0.68 |
| ▸ | GALR3 | O60755 | 2/20 | 0.64 |
| ▸ | NR2F2 | P24468 | 2/20 | 0.64 |
| ▸ | RAB9A | P51151 | 2/20 | 0.64 |
| ▸ | CDK1 | P06493 | 3/20 | 0.63 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.63 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.63 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 4/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | JAK2 | O60674 | 1/20 | 0.59 |
| ▸ | JAK1 | P23458 | 1/20 | 0.59 |
| ▸ | CDK2 | P24941 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | PDE4A | P27815 | 1/20 | 0.57 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 6-Benzylaminopurine SCHEMBL29772173 | 0.81 | LMNA (0.62) | EGFRGALR3NR2F2RAB9ACDK1 | |
| 6-Benzylaminopurine SCHEMBL28824679 | 0.81 | LMNA (0.62) | EGFRGALR3NR2F2RAB9ACDK1 | |
| SCHEMBL6837710 | 0.81 | EGFR (1.00) | EGFRGALR3NR2F2RAB9ACDK1 | |
| 6-Benzylaminopurine SCHEMBL37357 | 0.81 | LMNA (0.62) | EGFRGALR3NR2F2RAB9ACDK1 | |
| 6-Benzylaminopurine SCHEMBL8378677 | 0.80 | LMNA (0.61) | EGFRGALR3NR2F2RAB9ACDK1 | |
| 6-Benzylaminopurine SCHEMBL218732 | 0.80 | LMNA (0.61) | EGFRGALR3NR2F2RAB9ACDK1 | |
| 6-Benzylaminopurine SCHEMBL11477799 | 0.80 | LMNA (0.61) | EGFRGALR3NR2F2RAB9ACDK1 | |
| SCHEMBL3239167 | 0.79 | CDK1 (1.00) | EGFRCDK1CCNB2CCNB1CCNB3 | |
| SCHEMBL13191911 | 0.79 | AURKA (0.62) | EGFRGALR3NR2F2RAB9ALMNA | |
| SCHEMBL14778602 | 0.79 | CSF1R (0.54) | EGFRGALR3NR2F2RAB9ACDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2301628-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | Zalicus Inc. (US) | 2011-03-30 | — | — | EP | claimed |
| EP-2279742-A2 | Combinations for the treatment of immunoinflammatory disorders | Zalicus Inc. (US) | 2011-02-02 | — | — | EP | claimed |
| EP-2070550-A1 | Use of combinations comprising a corticosteroid and a pyrimidopyrimidine in the treatment of inflammatory diseases | Combinatorx, Incorporated (US) | 2009-06-17 | — | — | EP | claimed |
| US-20090005358-A1 | Compositions and methods for treating medical conditions | LG CHEM, LTD. (KR) | 2009-01-01 | — | — | US | claimed |
| WO-2009002507-A1 | COMPOSITIONS AND METHODS FOR TREATING MEDICAL CONDITIONS | COMBINATORX, INCORPORATED (US) | 2008-12-31 | — | — | WO | claimed |
| US-20080025965-A1 | Methods and compositions for the treatment of diseases or conditions associated with increased C-reactive protein levels | COMBINATORX, INCORPORATED | 2008-01-31 | — | — | US | claimed |
| US-20080003213-A1 | Methods and compositions for the treatment of diseases or conditions associated with increased C-reactive protein, interleukin-6, or interferon-gamma levels | COMBINATORX, INC. | 2008-01-03 | — | — | US | claimed |
| WO-2007146012-A1 | TREATMENT OF PERIODONTAL DISEASE ASSOCIATED WITH INCREASED C-REACTIVE PROTEIN LEVELS | COMBINATORX, INCORPORATED (US) | 2007-12-21 | — | — | WO | claimed |
| WO-2007139753-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASES OR CONDITIONS ASSOCIATED WITH INCREASED C-REACTIVE PROTEIN, INTERLEUKIN-6, OR INTERFERON-GAMMA LEVELS | COMBINATORX, INCORPORATED (US) | 2007-12-06 | — | — | WO | claimed |
| US-20070010502-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | COMBINATORX INC. (US) | 2007-01-11 | — | — | US | claimed |
| EP-1448205-A4 | COMBINATIONS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX INC (US) | 2007-01-03 | — | — | EP | claimed |
| EP-1448205-A2 | COMBINATIONS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | Combinatorx, Incorporated (US) | 2004-08-25 | — | — | EP | claimed |
| US-20030119786-A1 | Combinations for the treatment of immunoinflammatory disorders | ZALICUS INC. | 2003-06-26 | — | — | US | claimed |
| WO-2003030823-A2 | COMBINATIONS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2003-04-17 | — | — | WO | claimed |
| US-20120058979-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | ZALICUS INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-8080553-B2 | Methods and reagents for the treatment of immunoinflammatory disorders | ZALICUS INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-20110223621-A1 | COMBINATIONS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INC. | 2011-09-15 | — | — | US | disclosed |
| EP-1448205-A2 | COMBINATIONS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | Combinatorx, Incorporated (US) | 2004-08-25 | — | — | EP | disclosed |
| US-20030119786-A1 | Combinations for the treatment of immunoinflammatory disorders | ZALICUS INC. | 2003-06-26 | — | — | US | disclosed |
| WO-2003030823-A2 | COMBINATIONS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005358-A1 | Compositions and methods for treating medical conditions | ITCH, TSLP, P2RX5 | EGFR 706/4885GALR3 661/4885NR2F2 3608/4885 |
| US-20070010502-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | IL5, TPMT, TSLP | EGFR 4049/4885GALR3 2900/4885NR2F2 2410/4885 |
| US-20080025965-A1 | Methods and compositions for the treatment of diseases or conditions associated with increased C-reactive protein levels | TYMP, TTR, TPMT | EGFR 1562/4885GALR3 3254/4885NR2F2 2455/4885 |
| US-20030119786-A1 | Combinations for the treatment of immunoinflammatory disorders | IL5, TSLP, TPMT | EGFR 4428/4885GALR3 3618/4885NR2F2 2340/4885 |
| US-20080003213-A1 | Methods and compositions for the treatment of diseases or conditions associated with increased C-reactive protein, interleukin-6, or interferon-gamma levels | IFNG, IL6, IL36G | EGFR 1336/4885GALR3 3635/4885NR2F2 2602/4885 |
| US-20120058979-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | IL5, TPMT, TSLP | EGFR 4049/4885GALR3 2900/4885NR2F2 2410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.